Syndicated reports on market outlook, epidemiology, emerging therapies, current treatment and market access, across oncology, rare and non-oncology indications.
Preview the scope and sample pages of any report in the store, then get 10% off when you buy it.
Validated patient numbers, funnels and disease burden for 450+ indications across 30+ countries.
Payer research across 31+ markets to shape your pricing, reimbursement and launch strategy.
Weigh every asset on clinical, commercial, regulatory and competitive evidence, and invest where value is highest.
Test your assumptions with interviews and surveys drawn from our 8,500+ physician expert panel.
Patient-based forecasts that combine epidemiology, treatment dynamics, pricing and competition.
Live coverage of major meetings such as ESMO 2026, with the data and takeaways that matter to you.



















Thelansis’s “Obstructive Sleep Apnea (OSA) Emerging Therapy,...
Thelansis’s “VEXAS Syndrome Emerging Therapy, with Unmet Nee...
Thelansis’s “Antiphospholipid Syndrome (APS) Emerging Therap...
See Thelansis insights first in Google’s Top Stories when you search the topics you follow.
We tailor reports to the indication, markets and questions you need.
Not sure which report fits your question? Our team will point you to the right one.
Reports you open will show here.
Showing 1 to 10 of 2,616 reports
Loading...Thelansis’s “Dry Age-Related Macular Degeneration Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product pr...
Thelansis’s “Dry Age-Related Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription shar...
Thelansis’s “Generalized Myasthenia Gravis (gMG) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product pro...
Thelansis’s “Niemann-Pick Type C (NPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPP...
Thelansis’s “Progressive Multiple Sclerosis (PMS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product pr...
Thelansis’s “Progressive Multiple Sclerosis (PMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription shar...
Thelansis’s “Myelofibrosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial de...
Thelansis’s “Myelofibrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive...
Thelansis’s “Secondary Progressive Multiple Sclerosis (SPMS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target...
Thelansis’s “Cystic Fibrosis (CF) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), t...
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.